Fighting Friedreich’s ataxia: A pediatric cardiologist’s journey of innovation and collaboration
R. Mark Payne, MD, has pioneered a promising treatment for Friedreich's ataxia, a degenerative nervous system condition with no present cure. Payne's journey with his drug, CTI-1601, involved extensive collaboration with numerous organizations, partners and colleagues over the last two decades. His innovative approach and entrepreneurial spirit have resulted in a treatment that offers new hope to patients and their families.
Genetic detectives unlock 16-year mystery
Laura Gates | Feb 13, 2024
Powerful new genomic sequencing tool available to researchers
IU School of Medicine | Aug 29, 2023
IU researchers uncover mysteries behind immune response to hemophilia A treatment
Jackie Maupin | Aug 10, 2023
IU researchers investigate the protein BVES and its important role in muscular dystrophy
Jackie Maupin | Apr 05, 2023
Researchers uncover new drug combination to treat rare pediatric cancer called JMML
Jackie Maupin | Apr 04, 2023
Case solved: Undiagnosed Rare Disease Clinic resolves family's 15-year journey to diagnosis
Laura Gates | Feb 23, 2023
Diagnostic event helps dozens
Caitlin VanOverberghe | Jun 17, 2022
Undiagnosed Rare Disease Clinic uses tech and teamwork to solve medical mysteries
Laura Gates | Feb 25, 2022
New publication means improved outcomes for children with Kawasaki disease
Anna Carrera | Nov 09, 2021